FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Shams Soheil
2. Issuer Name and Ticker or Trading Symbol

Bionano Genomics, Inc. [ BNGO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Informatics Officer
(Last)          (First)          (Middle)

C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100
3. Date of Earliest Transaction (MM/DD/YYYY)

11/1/2021
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $5.40 11/1/2021  A   400000     (1)11/1/2031 Common Stock 400000 $0.00 400000 D  

Explanation of Responses:
(1) 25% of the shares subject to the option shall vest and become exercisable on October 18, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from October 18, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2020 Inducement Plan) through each such applicable vesting date and the terms of the Company's 2020 Inducement Plan.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Shams Soheil
C/O BIONANO GENOMICS, INC.
9540 TOWNE CENTRE DRIVE, SUITE 100
SAN DIEGO, CA 92121


Chief Informatics Officer

Signatures
/s/ R. Erik Holmlin, Attorney-in-Fact11/2/2021
**Signature of Reporting PersonDate

Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bionano Genomics Charts.
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bionano Genomics Charts.